Not Your Father’s Data Center: Mining for bitcoin and other cryptocurrencies

Fred Thiel, CEO of Marathon Digital Holdings, one of the largest bitcoin mining operations in North America, joined host Raymond Hawkins to discuss cryptocurrency. From blockchain to bitcoin, Thiel covered it all, including all the nooks and crannies in between.

“The blockchain is essentially a chain of linked blocks that each block consists of a certain number of transactions,” Thiel said. “If you think about a ledger, like your check register, if you have a checkbook and you write a bunch of checks, you write them down in your check register at the month you get a statement from your bank. So, those types of transactions are formed into blocks. The underlying software for the blockchain allows miners to do this process of assembling these transactions into blocks. Then you run a mathematical cryptographical proof on this data, and that generates a hash. And that hash has to have a certain value to it. And when it gets that hash, it then has to be equal to or less than a specific target number that the blockchain is looking for.”

Miners who guess that number correctly will win the block, publish the block, other nodes validate the block, and then the miner will receive a block award.

In the high-stakes game of blockchain mining, with limited numbers of bitcoin issued per day, Thiel said there is a competition to it. “If you have one miner, and you plug it in, you’re not going to get a fraction of a bitcoin every day,” Thiel said. “And so what miners do is, miners, pool their miners together. And aggregating and cooperating, a group of miners in a pool, you have a more hash-rate you’re contributing to the overall network, and a higher likelihood you’re going to win blocks, and the block rewards can be evenly distributed amongst members of the pool.”

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More